The venture group that has launched a fleet of new biotechs in recent years, piecing together billions in syndicate cash, has $824 million more to build its next generation of life sciences companies.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.Free Subscription